Moreover, there are concerns about the use of immunosuppressants such as corticosteroids at the beginning of treatment with PD-1/PD-L1 inhibitors in AD patients, since they may impair the efficacy of the immunotherapy in these patients, exacerbate the existing disease, or alter the risk of new irAEs. The gene discussed is PDCD1; the disease is Alzheimer disease.